Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/Novopharm merger update

Executive Summary

Teva has signed a letter of intent to acquire the privately-held Canadian generic firm Novopharm, Ltd. for 4.8 mil. shares of Teva common stock (valued at approximately $264 mil.). However, completion of the agreement awaits "the resolution to Teva's satisfaction of certain issues now pending before a Canadian court relating to the scope and duration of an existing injunction against Novopharm." Teva is "hopeful that a court decision will be rendered within the next few months"
UsernamePublicRestriction

Register

PS035278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel